Smart radiation: new trial aims to zap lingering lymphoma cells
NCT ID NCT07517705
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether using a blood test (MRD) after two cycles of chemoimmunotherapy can guide the use of low-dose radiation in patients with diffuse large B-cell lymphoma. Patients with detectable cancer DNA in their blood may receive targeted radiation to remaining spots on PET scans, while those with no detectable DNA continue standard therapy. The goal is to see if this personalized approach is feasible and safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Low-dose radiation therapy combined with standard chemoimmunotherapy (R-CHOP or similar regimens)
What this could lead to
If successful, this approach could help personalize treatment for lymphoma, potentially improving response rates by targeting residual disease early.
What could go wrong
This is a small, early-phase feasibility study (50 participants) and not yet recruiting. The added radiation may not improve outcomes and could increase side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred & Pamela Buffet Cancer Center
Omaha, Nebraska, 68198, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••